Inventor
HANSEN JOSHUA
US47 patents
⚠️ This page may combine multiple inventors who share the name “HANSEN JOSHUA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CELGENE CORP
30 patentsUS9499514B2Nov 22, 2016
Antiproliferative compounds and methods of use thereof
CELGENE CORP28 citations93
US10357489B2Jul 23, 2019
Antiproliferative compounds and methods of use thereof
CELGENE CORP20 citations92
US11149007B2Oct 19, 2021
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP14 citations84
US11325889B2May 10, 2022
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP11 citations83
US10227325B2Mar 12, 2019
Antiproliferative compounds, and their pharmaceutical compositions and uses
CELGENE CORP6 citations83
US9938254B2Apr 10, 2018
Antiproliferative compounds, and their pharmaceutical compositions and uses
CELGENE CORP5 citations83
US11185543B2Nov 30, 2021
Antiproliferative compounds and methods of use thereof
CELGENE CORP5 citations82
US9968596B2May 15, 2018
Antiproliferative compounds and methods of use thereof
CELGENE CORP8 citations82
US9808451B2Nov 7, 2017
Antiproliferative compounds and methods of use thereof
CELGENE CORP12 citations82
US11634407B2Apr 25, 2023
Cereblon binding compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP5 citations73
US11241423B2Feb 8, 2022
Antiproliferative compounds and methods of use thereof
CELGENE CORP2 citations72
US10969381B2Apr 6, 2021
Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile
CELGENE CORP1 citations72
US10618883B2Apr 14, 2020
Antiproliferative compounds, and their pharmaceutical compositions and uses
CELGENE CORP1 citations72
US11873283B2Jan 16, 2024
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP2 citations71
US11739075B2Aug 29, 2023
Cereblon binding compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP3 citations71
US11726080B2Aug 15, 2023
Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile
CELGENE CORP1 citations71
US11560371B2Jan 24, 2023
Cereblon binding compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP3 citations71
US11365184B2Jun 21, 2022
Antiproliferative compounds, and their pharmaceutical compositions and uses
CELGENE CORP0 citations62
US12510533B2Dec 30, 2025
Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile
CELGENE CORP0 citations61
US12404241B2Sep 2, 2025
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP0 citations61
US12227490B2Feb 18, 2025
Cereblon binding compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP0 citations61
US12103920B2Oct 1, 2024
Cereblon binding compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP0 citations61
US11945804B2Apr 2, 2024
Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP0 citations61
US11358952B2Jun 14, 2022
Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP1 citations60
US12577223B2Mar 17, 2026
Processes for preparing 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
CELGENE CORP0 citations59
US12029738B2Jul 9, 2024
Antiproliferative compounds and methods of use thereof
CELGENE CORP0 citations59
US11312699B2Apr 26, 2022
Processes for preparing 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
CELGENE CORP0 citations59
US12486281B2Dec 2, 2025
Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP0 citations56
US11306101B2Apr 19, 2022
Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
CELGENE CORP0 citations56
US10675281B2Jun 9, 2020
Antiproliferative compounds and methods of use thereof
CELGENE CORP0 citations51
SIGNAL PHARM LLC
10 patentsUS9512124B2Dec 6, 2016
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC32 citations96
US9737541B2Aug 22, 2017
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC12 citations91
US9556126B2Jan 31, 2017
Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC10 citations82
US9156798B2Oct 13, 2015
Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC5 citations82
US10940152B2Mar 9, 2021
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC1 citations72
US10646493B2May 12, 2020
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC1 citations72
US10398700B2Sep 3, 2019
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC2 citations72
US10149849B2Dec 11, 2018
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC2 citations72
US9783505B2Oct 10, 2017
Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC2 citations71
US11590139B2Feb 28, 2023
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SIGNAL PHARM LLC0 citations61